再鼎医药有限公司（09688）于2026年2月5日披露2026年1月股份变动月报表。截至1月31日，公司注册股本维持5,000,000,000股，面值为每股0.000006美元，注册股本总额继续保持30,000美元。
报告期内，已发行普通股总数维持在1,119,628,030股，未有新增发行、回购或注销股份活动。公告显示，公司符合适用的公眾持股量要求。
在股权激励方面，多个股权激励计划的部分期权及限制性股份单位（RSU）于本月失效，另有2015年股权激励计划涉及合计7,350股期权行使，但皆以公司现有已发行股份兑现，未导致新增发行。整体而言，截至1月底，公司已发行股份总数保持不变。
公司在公告中确认，所有股份发行及转让活动均遵守香港联交所《上市规则》及其他法律法规。该份月报表由公司秘书F.Ty Edmondson签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.